PLYMOUTH, MA -- (MARKET WIRE) -- January 04, 2007 -- Harvest Technologies Corp. (www.harvesttech.com) announced today that Berthold Amann, MD, a specialist in vascular medicine, has received IRB approval to begin a 90-patient clinical trial at the Berlin (Germany) Vascular Center of Franziskus Hospital using Harvest Technologies' BMAC device -- a point-of-care system for concentrating autologous bone marrow stem cells -- to treat patients with end-stage Critical Limb Ischemia (CLI) who face leg amputation. CLI is the later stage of Peripheral Arterial Disease (PAD) -- clogged arteries, particularly in the lower legs. Patients with CLI are at extreme risk for amputation. Reportedly, about 160,000 amputations are performed each year in the U.S. as a result of this condition (source: The Sage Group).
